News | March 11, 2011

Texas Children's First to Begin Certification Process for Artificial Heart


March 11, 2011 – Texas Children's has become the world's first pediatric hospital to complete the first phase of certification to implant the SynCardia temporary Total Artificial Heart. The hospital intends to use the device as a bridge to transplant for their patients who received a heart transplant as children and now require mechanical support as a bridge to their second transplant.

The 15-member training team, which included cardiologists, critical care intensivists, anesthesiologists, nursing specialists and hemotologists, was led by David L.S. Morales, M.D., pediatric cardiovascular surgeon and director of mechanical circulation support at Texas Children's Hospital. This first-phase of certification prepares the team for future implantation of the device into patients who meet specific body-size qualifications.

Similar to a heart transplant, the Total Artificial Heart replaces both failing ventricles and the four cardiac valves. Once implanted, it pumps up to 9.5 liters per minute through both ventricles to provide increased blood flow to vital organs such as the brain, kidneys and liver. Unlike a donor heart, the device is instantly available before the patient's organs begin to fail and doesn't require expensive, anti-rejection medication, which can cause subsequent complications.

"Over the past few years as a transplant surgeon at Texas Children's Hospital, I have witnessed several patients who needed a second transplantation, but died before a donor heart became available," said Morales. "Those patients would have been excellent candidates for an immediately-available heart. The Total Artificial Heart is the only device that allows us to remove the failing donor heart completely and bridge patients to a second transplant without immunosuppressive therapy."

Of the more than 20 patients currently listed for a heart transplant at Texas Children's, more than 20 percent are waiting for their second donor heart. Since its inception in 1984, Texas Children's heart transplantation program has grown into one of the largest and most successful of its kind in the nation, having transplanted 248 pediatric patients.

For more information: www.syncardia.com, www.texaschildrens.org


Related Content

News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
News | Ventricular Assist Devices (VAD)

April 28, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers to the possibility that ...

Home April 28, 2022
Home
Subscribe Now